Crossmark Global Holdings Inc. Decreases Stock Position in Fresenius Medical Care AG (NYSE:FMS)

Crossmark Global Holdings Inc. cut its holdings in Fresenius Medical Care AG (NYSE:FMS) by 6.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,197 shares of the company’s stock after selling 2,838 shares during the period. Crossmark Global Holdings Inc.’s holdings in Fresenius Medical Care were worth $748,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Moran Wealth Management LLC purchased a new stake in shares of Fresenius Medical Care in the 4th quarter worth about $3,247,000. Guardian Capital Advisors LP lifted its holdings in shares of Fresenius Medical Care by 16.7% during the 4th quarter. Guardian Capital Advisors LP now owns 123,715 shares of the company’s stock valued at $2,556,000 after acquiring an additional 17,725 shares in the last quarter. Partnership Wealth Management LLC acquired a new position in shares of Fresenius Medical Care during the 4th quarter valued at $2,340,000. Triasima Portfolio Management inc. acquired a new position in shares of Fresenius Medical Care during the 1st quarter valued at $1,293,000. Finally, Corient Private Wealth LLC lifted its holdings in shares of Fresenius Medical Care by 164.6% during the 4th quarter. Corient Private Wealth LLC now owns 66,134 shares of the company’s stock valued at $1,378,000 after acquiring an additional 41,139 shares in the last quarter. 8.25% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care Trading Up 0.2 %

Fresenius Medical Care stock opened at $19.39 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.45. The firm has a 50-day moving average price of $19.30 and a two-hundred day moving average price of $19.90. The firm has a market capitalization of $11.38 billion, a price-to-earnings ratio of 21.79, a PEG ratio of 1.01 and a beta of 0.90. Fresenius Medical Care AG has a 52-week low of $16.37 and a 52-week high of $24.48.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.38. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. The business had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.28 billion. Sell-side analysts expect that Fresenius Medical Care AG will post 1.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on FMS shares. StockNews.com initiated coverage on shares of Fresenius Medical Care in a research note on Thursday. They set a “strong-buy” rating on the stock. Truist Financial decreased their price target on shares of Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating for the company in a report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $22.00.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.